Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects
Clinical and Experimental Allergy, ISSN: 0954-7894, Vol: 35, Issue: 7, Page: 880-883
2005
- 20Citations
- 11Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations20
- Citation Indexes19
- 19
- CrossRef12
- Clinical Citations1
- PubMed Guidelines1
- Captures11
- Readers11
- 11
Article Description
Background: Local nasal immunotherapy is accepted as an alternative to the injection route for allergic rhinitis. Despite this, little is known about the kinetics of the allergen after nasal delivery in allergic subjects. Objective: We aimed at assessing the biodistribution of I-radiolabelled Par j 1 in Parietaria-allergic subjects, in comparison with healthy volunteers. Methods Purified Par j 1 was radiolabelled with I and sprayed into the nostrils of three control subjects and three Parietaria-allergic volunteers. Dynamic and static scintigraphic images of the head were recorded at serial times and blood samples were obtained to measure the plasma radioactivity, and to assess the presence of circulating radiolabelled species by gel chromatography. Results: In Parietaria-sensitized subjects, the radiolabelled allergen was rapidly cleared from the nasal cavity and transported to pharynx, and little local persistence was seen. This differed from healthy subjects where nasal clearance of the tracer was slower and nasal radioactivity persisted up to 24 h. The increase in plasma radioactivity paralleled swallowing of the allergen in both groups, and plasma Chromatographic profile did not differ between allergic and healthy volunteers. Conclusions: Sensitization to the allergen affects its local biodistribution. Gastrointestinal absorption is relevant also for the intranasal route. © 2005 Blackwell Publishing Ltd.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know